HomeComparePRTK vs CHD

PRTK vs CHD: Dividend Comparison 2026

PRTK yields 1433.77% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRTK wins by $465580976.90M in total portfolio value
10 years
PRTK
PRTK
● Live price
1433.77%
Share price
$2.23
Annual div
$31.97
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$465580976.93M
Annual income
$409,409,349,290,672.40
Full PRTK calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — PRTK vs CHD

📍 PRTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRTKCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRTK + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRTK pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRTK
Annual income on $10K today (after 15% tax)
$121,870.18/yr
After 10yr DRIP, annual income (after tax)
$347,997,946,897,071.50/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, PRTK beats the other by $347,997,946,895,964.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRTK + CHD for your $10,000?

PRTK: 50%CHD: 50%
100% CHD50/50100% PRTK
Portfolio after 10yr
$232790488.48M
Annual income
$204,704,674,645,987.50/yr
Blended yield
87.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

PRTK
No analyst data
Altman Z
-9.7
Piotroski
4/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRTK buys
0
CHD buys
0
No recent congressional trades found for PRTK or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRTKCHD
Forward yield1433.77%1.28%
Annual dividend / share$31.97$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$465580976.93M$26.4K
Annual income after 10y$409,409,349,290,672.40$1,302.64
Total dividends collected$461472805.42M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PRTK vs CHD ($10,000, DRIP)

YearPRTK PortfolioPRTK Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$154,077$143,376.68$10,857$157.30+$143.2KPRTK
2$2,229,442$2,064,579.75$11,814$196.49+$2.22MPRTK
3$30,304,969$27,919,466.07$12,887$245.97+$30.29MPRTK
4$387,109,855$354,683,538.63$14,097$308.68+$387.10MPRTK
5$4,648,468,715$4,234,261,169.66$15,473$388.49+$4648.45MPRTK
6$52,493,108,361$47,519,246,835.85$17,046$490.55+$52493.09MPRTK
7$557,675,953,215$501,508,327,268.83$18,861$621.76+$557675.93MPRTK
8$5,576,078,691,653$4,979,365,421,713.55$20,973$791.47+$5576078.67MPRTK
9$52,496,848,258,695$46,530,444,058,626.19$23,454$1,012.51+$52496848.24MPRTK
10$465,580,976,927,476$409,409,349,290,672.40$26,398$1,302.64+$465580976.90MPRTK

PRTK vs CHD: Complete Analysis 2026

PRTKStock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Full PRTK Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this PRTK vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRTK vs SCHDPRTK vs JEPIPRTK vs OPRTK vs KOPRTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.